Aptinyx Inc Quick Ratio (APTX) starting from the first quarter 2023 to first quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Aptinyx Inc   (NASDAQ: APTX)

Aptinyx Inc 's Quick Ratio

APTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2023, Quick Ratio fell to 4.78 a new company low.

Within Major Pharmaceutical Preparations industry 263 other companies have achieved higher Quick Ratio than Aptinyx Inc in first quarter 2023. While Quick Ratio total ranking in the first quarter 2023 has deteriorated compared to the prior quarter from 220 to 888.

Explain Quick Ratio?
How much Cash & cash equivalents APTX´s has?
What are APTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

APTX Quick Ratio (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1
Y / Y Current Liabilities Change 432.13 % 465.76 % -84.79 % 385.25 % 4.66 %
Y / Y Cash & cash equivalent Change -55.5 % -47.04 % -46.86 % -34.02 % -31.77 %
Quick Ratio MRQ 4.78 15.97 140.47 40.49 57.17
APTX's Total Ranking # 888 # 220 # 27 # 27 # 47
Seq. Current Liabilities Change 164.93 % 642.41 % -77.49 % 20.21 % 181.67 %
Seq. Cash & cash equivalent Change -20.7 % -15.59 % -21.91 % -14.87 % -5.62 %



Quick Ratio first quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 264
Healthcare Sector # 439
Overall Market # 888


Quick Ratio Statistics
High Average Low
297.76 75.25 4.78
(Jun 30 2021)   (Mar 31 2023)




Financial Statements
Aptinyx Inc 's Current Liabilities $ 9 Millions Visit APTX's Balance sheet
Aptinyx Inc 's Cash & cash equivalent $ 45 Millions Visit APTX's Balance sheet
Source of APTX's Sales Visit APTX's Sales by Geography


Cumulative Aptinyx Inc 's Quick Ratio

APTX's Quick Ratio for the trailling 12 Months

APTX Quick Ratio

 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth 160.29 % 34.27 % -23 % 76.55 % 9.7 %
Y / Y Cash & cash equivalent TTM Growth -45.18 % -39.26 % -33.96 % -19.97 % -9.2 %
Quick Ratio TTM 16.38 39.26 72.29 54.87 77.77
Total Ranking TTM # 3782 # 3184 # 3327 # 3178 # 3024
Seq. Current Liabilities TTM Growth 96.43 % 58.48 % -34.79 % 28.22 % 1.33 %
Seq. Cash & cash equivalent TTM Growth -18.03 % -13.94 % -14.08 % -9.54 % -9.19 %

Quick ratio ranking by company, industry and sector >> Back to APTX Financial Strength Comparisons >> Go to Compare APTX Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q1 2023 to $9.32 millions, cumulative Quick Ratio decreased to 16.38 below the Aptinyx Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 559 other companies have achieved higher Quick Ratio than Aptinyx Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 3184 to 3782.

Explain Quick Ratio?
How much Cash & cash equivalents APTX´s has?
What are APTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 560
Healthcare Sector # 1085
Within the Market # 3782


trailing twelve months Quick Ratio Statistics
High Average Low
32.33 23.33 10.53
(Jun 30 2021)   (Mar 31 2023)




Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2023 MRQ Cash & cash equivalentMar 31 2023 MRQ Current Liabilities
Cerevel Therapeutics Holdings Inc   13.14 $ 826.987  Millions$ 62.957  Millions
Virpax Pharmaceuticals Inc   13.13 $ 16.987  Millions$ 1.294  Millions
Relmada Therapeutics Inc  13.12 $ 132.442  Millions$ 10.097  Millions
Mineralys Therapeutics Inc   13.09 $ 138.246  Millions$ 10.560  Millions
Coya Therapeutics Inc   12.89 $ 16.320  Millions$ 1.266  Millions
Pyxis Oncology Inc   12.87 $ 149.349  Millions$ 11.601  Millions
Adicet Bio Inc   12.80 $ 231.640  Millions$ 18.095  Millions
Oric Pharmaceuticals Inc   12.76 $ 189.629  Millions$ 14.867  Millions
Ataibeckley Inc   12.73 $ 249.883  Millions$ 19.636  Millions
Generation Bio Co   12.70 $ 288.649  Millions$ 22.737  Millions
Milestone Pharmaceuticals Inc   12.68 $ 100.953  Millions$ 7.963  Millions
Anaptysbio Inc   12.63 $ 431.151  Millions$ 34.124  Millions
Immutep Limited  12.63 $ 82.233  Millions$ 6.511  Millions
Cryoport inc   12.60 $ 523.832  Millions$ 41.583  Millions
Sensei Biotherapeutics Inc   12.59 $ 95.505  Millions$ 7.583  Millions
Indaptus Therapeutics Inc   12.59 $ 21.681  Millions$ 1.723  Millions
Arbutus Biopharma Corp  12.46 $ 240.464  Millions$ 19.294  Millions
Nkarta Inc   12.45 $ 323.341  Millions$ 25.981  Millions
Io Biotech Inc   12.41 $ 128.527  Millions$ 10.357  Millions
Landos Biopharma Inc   12.02 $ 50.006  Millions$ 4.160  Millions
Cormedix Inc   11.89 $ 55.601  Millions$ 4.675  Millions
Xortx Therapeutics inc   11.69 $ 3.448  Millions$ 0.295  Millions
Centessa Pharmaceuticals Plc  11.66 $ 346.229  Millions$ 29.686  Millions
Cocrystal Pharma Inc   11.57 $ 33.981  Millions$ 2.937  Millions
Lisata Therapeutics Inc   11.56 $ 61.095  Millions$ 5.286  Millions
Lumos Pharma Inc   11.56 $ 57.983  Millions$ 5.017  Millions
Ideaya Biosciences Inc   11.38 $ 339.470  Millions$ 29.820  Millions
Crinetics Pharmaceuticals Inc   11.25 $ 296.122  Millions$ 26.321  Millions
Jade Biosciences Inc   11.18 $ 118.929  Millions$ 10.637  Millions
Kinnate Biopharma Inc   11.07 $ 200.981  Millions$ 18.155  Millions

Date modified: 2026-09-08T15:10:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.